SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-24-104372
Filing Date
2024-09-30
Accepted
2024-09-30 17:13:32
Documents
7
Period of Report
2024-10-31

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2425198d1_def14a.htm DEF 14A 490948
2 GRAPHIC tm2424296d1_pre14asp01img01.jpg GRAPHIC 2945
3 GRAPHIC tm2424296d1_pre14aimg001.jpg GRAPHIC 147510
4 GRAPHIC tm2424296d1_pre14aimg002.jpg GRAPHIC 140076
5 GRAPHIC tm2424296d1_pre14asp01img02.jpg GRAPHIC 473266
6 GRAPHIC proxy1.jpg GRAPHIC 311016
7 GRAPHIC proxy2.jpg GRAPHIC 204956
  Complete submission text file 0001104659-24-104372.txt   2255195
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-12584 | Film No.: 241340372
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)